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Abstract
The administration of vaccines is not usually recommended in pregnant women because of a fear of severe adverse events for the fetus.
However, contraindication to vaccination applies only to vaccines based on live attenuated viruses for the theoretical possibility that
they might infect the fetus. In contrast, the use of several inactivated vaccines is useful and recommended. As a result of the transpla-
cental passage of antibodies, maternal immunization can reduce the risk of vaccine-preventable diseases that may occur in the first
months of life before the start or completion of the suggested vaccination schedule. One of the best examples is vaccination against
influenza that can protect pregnant women from a disease that can lead to hospitalization and death in a significantly higher number of
cases than in the general population and can induce protective specific antibody levels as well as being effective in infants in the first
months of life. Other examples are vaccinations against tetanus, pertussis, pneumococcal infections and Haemophilus influenzae type b infec-
tion. This review analyses the advantages and limitations of maternal immunization as revealed by experience and the main publications.
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The administration of inactivated vaccines can be useful in
pregnant women [1]. As a result of the transplacental pas-
sage of antibodies, maternal immunization can reduce the
risk of vaccine-preventable diseases that may occur in the
first months of life before the start or completion of the sug-
gested vaccination schedule [1].
The best examples are vaccinations against tetanus, pertus-
sis, pneumococcal infections, Haemophilus influenzae type b
(Hib) infection and influenza. Contraindication to vaccination
applies only to vaccines based on live attenuated viruses for
the theoretical possibility that they might infect the fetus.
However, despite the importance of vaccinations for pregnant
women and their infants, vaccination coverage in pregnant
women has remained very poor, even in the countries in
which different vaccinations have been officially recommended
for a long time or in which recommendations for vaccine use
during pregnancy have been recently enhanced [1].
Transfer of maternal antibody
The transport of IgG across the placenta is an active, selec-
tive, intracellular process in which IgG1 and IgG3 are prefer-
entially transferred [2]. The transfer begins at about 17 weeks
and increases as gestation advances. By 33 weeks of gestation,
maternal and fetal IgG are at equivalent levels. By 40 weeks of
gestation, the fetal IgG concentration is higher than that of
the mother. The efficiency of this process depends on multi-
ple factors including placental abnormalities, total IgG concen-
tration in maternal blood, the type of vaccine, the time
between vaccination of the mother and delivery, the gesta-
tional age of the fetus at birth and the concentration of vac-
cine-specific IgG and IgG subclasses in maternal blood [2].
Diseases such as malaria or human immunodeficiency virus
(HIV) infection have a negative impact on placental integrity
and consequently on transfer of maternal antibody to the
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fetus. For example, it has been shown that malaria affects
the ability of the placenta to transport IgG tetanus antibodies
[3] as well as Hib polyribosylphosphate (PRP) -specific IgG
[4]. Similarly, it has been demonstrated that a high HIV load
is associated with a reduced transfer of tetanus [5] as well as
measles antibodies to the fetus [6].
Prevention of tetanus
In developed countries, neonatal tetanus is now little more
than a medical curiosity because the extensive use of meth-
ods ensuring safe delivery and reducing abortions, the sys-
tematic use of umbilical cord care practices, and the
universal administration of tetanus vaccination has practically
eliminated the disease. However, although significantly
reduced by a number of international initiatives, neonatal tet-
anus is still a considerable clinical problem in the developing
world and causes more than 100 000 deaths every year [7].
Maternal tetanus immunization is the most important
means of preventing neonatal tetanus, and the efficacy of tet-
anus toxoid has been known for about 50 years. In the early
1960s, it was found that giving pregnant women three doses
of fluid tetanus toxoid without adjuvant (equivalent to about
two doses of aluminium-absorbed tetanus toxoid (AATT))
could lead to a 94% reduction in deaths due to neonatal tet-
anus [8]. It was also found that no child born of women who
had received two or three doses of AATT in the 5 years
preceding delivery had died of the disease [9–12].
The decision to administer tetanus vaccine to a pregnant
immunocompetent woman strictly depends on the total
number of doses she has received in the past, and the age at
which they were received [13]. Only the administration of a
third dose some months after the second assures protection
for several years in about 98% of recipients [13]. This is fur-
ther prolonged by following the WHO recommendation of
five doses in 12–15 years starting from infancy, which is
believed to ensure protection for 20–25 years [13]. Most of
the neonates in industrialized countries are seroprotected
against tetanus because tetanus vaccine is repeatedly adminis-
tered during childhood. Prusa et al. [14] have recently evalu-
ated tetanus antibody levels in neonates in Austria and found
that 85.8% presented an antibody concentration of ‡0.1 IU/
mL, 9.1% showed low seropositivity, and only 5.1% of the
samples had undetectable antibody levels. In developing
countries, where only 2% of pregnant women had received
at least two doses of tetanus toxoid by 1989, pregnant
women were not protected for many years and most of
their children did not have measurable tetanus antibody lev-
els at birth [15]. This led to the implementation of carefully
planned tetanus vaccination campaigns in high-risk areas,
which targeted more than 94 million women and protected
more than 70 million with at least two doses of tetanus tox-
oid. However, the results of these initiatives cannot be pre-
cisely defined because the surveillance of neonatal tetanus has
hardly improved, and reporting is still <10% in countries in
which the disease remains a substantial public-health problem.
Prevention of pertussis
Despite vaccination, pertussis is relatively common in the
general population, and most severe in young infants who
have the highest hospitalization and complication rates
[16,17]. Almost all of the deaths associated with pertussis
occur in infants aged <6 months [18], most of whom are
too young to have received the primary series of pertussis
vaccine needed to establish immunity [17]. Moreover, they
are not protected even if born of mothers vaccinated in
childhood or previously infected by wild-type Bordetella per-
tussis because the immunity following vaccination or infection
is of limited duration.
The current strategy suggested by health authorities
worldwide to reduce pertussis-related problems in younger
infants is cocooning: i.e. the immunization of family members,
healthcare workers and other adults who are in close con-
tact with neonates in the postpartum period [19]. However,
it is likely that this measure is not very effective because it is
not easy to vaccinate all of the people who could transmit
B. pertussis to an infant [20]. Recently, a cross-sectional study
compared pertussis diagnoses in infants before and after rec-
ommendations to implement tetanus, diphtheria toxoids and
acellular pertussis (Tdap) vaccine for postpartum women
before hospital discharge [21]. Of 514 infants with pertussis,
378 (73.5%) were identified during pre-intervention and 136
(26.5%) during postintervention years. These groups were
similar in age (mean, 79.3 vs. 72 days; p 0.08), sex (males,
55% vs. 52%; p 0.48), length of hospitalization (mean, 9.7 vs.
10.7 days; p 0.62), and mortality (two deaths each; p 0.29).
After adjustment for age, sex and ethnicity, the proportions
of pertussis-infected infants potentially protected through
maternal postpartum immunization were similar for the two
periods (6.9% vs. 8.8%; OR 1.06; 95% CI 0.5–2.2; p 0.87).
Authors concluded that immunizing only postpartum moth-
ers with Tdap vaccine did not reduce pertussis illness in
infants £6 months of age [21]. Efforts should be directed at
immunizing all household and key contacts of newborns with
Tdap, not just mothers [21].
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In another study, Healy et al. [22] measured antibodies to
pertussis toxin (PT), filamentous haemagglutinin (FHA) and
fimbrial proteins (FIM) by validated IgG-specific ELISA in 64
maternal–umbilical cord serum pairs and in 61 of 64 infant
sera. Geometric mean concentrations (GMCs) of pertussis
antibodies and cord : maternal GMC ratios were calculated.
GMCs of maternal antibodies at delivery (ELISA units/mL)
were 2.4 for PT, 6.9 for FHA and 13 for FIM. Cord GMCs
were 169%, 178% and 157% of maternal delivery values for
PT, FHA and FIM, respectively, demonstrating active placental
transfer (p <0.001). Pertussis-specific IgG values for each anti-
gen decayed to below the threshold of detection by age
2 months. These findings show that despite efficient placental
transfer low maternal pertussis antibody levels and their rapid
decay in infant sera leave infants with little humoral protection
against pertussis [22]. These data support the rationale for
maternal or neonatal immunization, with acellular pertussis
vaccines, to prevent life-threatening pertussis in early infancy.
It was thought that administering pertussis vaccination to
women in the last trimester of pregnancy would interfere with
the active immunity of the child. However, studies by Englund
et al. [23] did not find that maternal antibodies against PT
interfered with the active immunization of the infant provided
by the usual schedule of acellular pertussis vaccine. Conse-
quently, even if interference occurs, it may not be relevant.
It is still unknown whether maternal vaccination against
pertussis is the best means of preventing pertussis in the
first 6 months of life. However, Gall et al. [24] have recently
compared antibody levels against five proteins of B. pertussis
(PT, pertactin (PRN), FHA and FIM 2/3) in samples of umbilical
cord blood taken from neonates born of mothers who had
received Tdap vaccination during pregnancy or of mothers
who were not vaccinated, and found that the former had sig-
nificantly higher concentrations of antibodies against PT
(p <0.001), FHA (p 0.002), PRN (p <0.001) and FIM 2/3
(p <0.001). Nevertheless, only specifically planned studies can
provide a definite answer to the question as to whether vacci-
nating pregnant women with pertussis vaccine is safe and effec-
tive in preventing pertussis in infants aged <6 months and can
be used without interfering with the infant’s antibody produc-
tion after subsequent vaccination. A number of trials are under
way in the USA, Canada and Australia [19], and it is hoped that
the answer will become available in a few years.
Pneumococcal vaccines
A number of common infants’ and children’s diseases are
caused by Streptococcus pneumoniae, including acute otitis
media, rhinosinusitis and pneumonia, and the pathogen is also
associated with the development of rarer but more severe dis-
eases such as meningitis and sepsis, which can lead to hospital-
ization and death. Infants aged <6 months (particularly those
living in developing countries) frequently suffer from these dis-
eases [25] and, unlike older children who can be efficiently
protected by the pneumococcal conjugate vaccine, they remain
without any immune protection even if they live in areas where
pneumococcal vaccine is included in the vaccination schedule.
The schedule for pneumococcal conjugate vaccine begins at
the age of 2–3 months, and complete protection against the
pneumococcal serotypes included in the vaccine is not reached
before the completion of the primary series (i.e. at the age of
5–6 months). Furthermore, the 23-valent pneumococcal poly-
saccharide vaccine (PPV) is not recommended for healthy
adults, and so pregnant women usually have poor pneumococ-
cal antibody concentrations that are limited to the serotypes
that have been the cause of a recent pneumococcal infection.
To protect infants during the vulnerable first few months of life
(i.e. before active immunization is possible or completed),
immunizing pregnant women with pneumococcal vaccine has
been considered because of the possibility that it could cause
the passage of specific pneumococcal IgG through the placenta
and a substantial amount of secretory IgA with breast milk.
Most of the studies of the impact of maternal immunization
on infants have used PPV which, with some exceptions [26],
has been found to be safe and immunogenic in pregnant women
in the USA, Papua New Guinea, Bangladesh and the Gambia
[27–29], and is currently recommended for pregnant women
belonging to risk groups for pneumococcal disease in at least
the USA and Australia [30]. In line with the results reported by
other authors [31,32], Holmlund et al. [33] have recently
shown that vaccinating mothers during pregnancy gives new-
borns significantly higher serum anti-polysaccharide antibody
concentrations for the first 4–5 months of life than those
observed in the infants of unvaccinated mothers. Furthermore,
it has also been reported that the vaccine can have different
effects on the concentrations of IgA antibodies in breast milk.
Obaro et al. [34] found that colostral s-IgA concentrations spe-
cific to all pneumococcal polysaccharide antigens were signifi-
cantly higher (p <0.05) in PPV recipients than in controls.
The clinical effect of administering PPV to pregnant
women has also been evaluated by measuring the rate of
infant pneumococcal infections in the first months of life and
by investigating the reduction in colonization rate during the
same period. O’Dempsey et al. [35] studied 149 pregnancies
and did not find any clear evidence of a positive effect
because, in comparison with the controls, the infants born of
vaccinated women had relative risks of developing pneumonia,
meningitis and acute otitis media of, respectively, 0.58 (95% CI
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0.18–1.41), 3.04 (95% CI 0.13–73.44) and 0.14 (95% CI 0.01–
2.75). Similarly unexciting results were reported by Munoz,
[36] who measured colonization rates in children born of vac-
cinated mothers and found that the vaccination did not reduce
the risk of pneumococcal colonization in the child until the
child was 16 months old. Furthermore, a study of HIV-
infected mothers found that the administration of PPV during
pregnancy led to a significant increase in both maternal and
infant antibodies, but did not protect infants aged <6 months
against nasopharyngeal pneumococcal carriage [37].
All of these data clearly indicate that, although the admin-
istration of PPV to pregnant women can induce higher breast
milk and infant blood antibody levels against the serotypes
included in the vaccine, there is still too little evidence to
support its use in the prevention of infant pneumococcal
infections [38]. Further studies are needed to evaluate this
possibility and to measure the possible interference of
maternal antibodies with the subsequent response to pneu-
mococcal conjugate vaccine.
Since the development of protein vaccines, various
attempts have been made to evaluate the impact of maternal
immunization with vaccines containing conserved pneumococ-
cal proteins that are capable of preventing all pneumococcal
infections regardless of the involved serotype. One of the
most recent is that of Francis et al., [39] who studied the pla-
cental transfer of naturally acquired antibodies against pneum-
olysin (Ply) and the pneumococcal surface protein A families 1
and 2 in relation to the onset of pneumococcal nasopharyn-
geal carriage in infants in Papua New Guinea. They found that
IgG antibodies against Ply were transferred from mother to
child, and delayed the age of first pneumococcal carriage in
high-risk infants. In contrast, maternal antibodies to PspA fam-
ily 1 did not protect, and were associated with a significantly
younger age of first carriage. Both of these findings are in line
with those of a previous study of infants living in a relatively
low-risk area [40]. Moreover, no associations were found
between maternal antibodies to PspA family 2 and the risk of
early carriage. The differences in the impact of the various
proteins seem to be strictly related to the degree of conser-
vation of the proteins themselves. This information is extre-
mely important for formulating an optimal pneumococcal
vaccine, and may have a substantial impact when vaccines are
used to prevent pneumococcal diseases in younger infants.
Haemophilus influenzae type b vaccine
In the countries in which plans for universal vaccination
against Hib have been largely implemented, the incidence of
invasive diseases due to this pathogen is extremely low and
there is no reason to vaccinate pregnant women to protect
their infants. However, the risk is greater where the vaccine
is rarely used, and vaccination of the mother can be consid-
ered on the basis of the epidemiology of the disease.
Attempts to evaluate maternal responses to Hib vaccine, the
transplacental transfer of antibody, and the effect of maternal
immunization on infant immune responses to subsequent
vaccine doses have been made for a number of years in
developing countries.
One good example is the study of polysaccharide–tetanus
protein conjugate (PRP-T) vaccine in pregnant Gambian
women by Mulholland et al. [4], which showed a marked
increase in total anti-PRP antibody levels that was greatest in
the women in their first or second pregnancy. Cord blood
anti-PRP IgG concentrations in the infants of the PRP-T
recipients were 61% of the maternal concentrations, and
geometric mean anti-PRP antibody concentrations in the vac-
cinated infants of vaccinated mothers at birth and at 2 and
5 months of age, were several times higher than those in the
vaccinated infants of unvaccinated mothers. At the age of
2 months, 60% of the infants of the vaccinated mothers and
26% of those of unvaccinated mothers had anti-PRP antibody
concentrations considered to be protective (>0.15 lg/mL).
The authors concluded that maternal immunization may help
to reduce the risk of Hib disease in areas where invasive Hib
disease frequently occurs in infants aged <6 months.
Inactivated influenza vaccines
Between 10% and 30% of children suffer from influenza
every year, which causes substantial medical, social and eco-
nomic problems [41]. Those aged <6 months are at highest
risk of severe disease and hospitalization: Poehling et al. [42]
found that the hospital admission rates for laboratory-con-
firmed influenza are about five times higher in children aged
0–5 months than in those aged 6–23 months. Mortality rates
are also highest in children aged <6 months: 0.88 cases per
100 000 children [43]. Young infants with chronic underlying
diseases (particularly respiratory conditions) are at greatest
risk of severe disease, but the incidence of healthy infants
requiring hospitalization is quite similar to that of high-risk
adults [44–47].
Preventing influenza in these subjects would be extremely
useful but, unfortunately, none of the available influenza vac-
cines is licensed for children aged <6 months because of
poor immunogenicity (as in the case of the traditional triva-
lent influenza vaccines, TIVs) or because of a fear of severe
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adverse events, as in the case of adjuvanted-TIVs or live
attenuated influenza vaccine (LAIV). The official strategies for
protecting younger infants are usually limited to washing
hands, avoiding contact with people infected with influenza,
and vaccinating close contacts, and their effectiveness has
not been defined [48].
Influenza vaccine is recommended throughout the world
for pregnant women who are at risk because of underlying
chronic disease and, in a number of countries, for healthy
pregnant women in order to protect them from a disease
that can lead to hospitalization and death in a significantly
higher number of cases than in the general population [49–
54]. As the IgG antibodies against influenza evoked by mater-
nal vaccination cross the placenta [55], and additional IgA
antibodies are transferred via breast milk [56], it is thought
that vaccinating pregnant mothers may also protect their
babies in the first months of life, so solving the problem of
the poor immunogenicity of TIV in young infants.
Some studies have collected data suggesting that maternal
influenza vaccination can induce protective specific antibody
levels in the infant. Englund et al. [57] conducted a small,
prospective, randomized and blinded trial in which TIV was
administered to pregnant women in weeks 32–36 of gesta-
tion and compared with no vaccination: the children born of
vaccinated mothers had significantly higher IgG antibodies
against vaccine antigens at birth and at 2 months of age. In
addition, no IgM antibodies against vaccine antigens could be
demonstrated in cord or infant serum, and there were blasto-
genic responses to influenza A by neonatal and infant lympho-
cytes, although these were demonstrable in lymphocytes
taken from all of the women who received TIV [57]. These
findings clearly confirmed that the antibodies had been pas-
sively transferred from the mother, and that no direct immune
response to influenza antigens had occurred in the children.
Similar findings have recently been reported by Puleston
et al. [58] and Zuccotti et al. [59], who used an adjuvanted
TIV specifically prepared for the 2009 pandemic. Puleston
et al. [58] evaluated humoral immunity in mother–infant pairs
of which the mothers may or may not have received the
pandemic influenza vaccine, and found that the reverse
cumulative distribution percentage curves of haemagglutinin
dilution (HAI) demonstrated background immunity in 25–
30% of the babies of unvaccinated mothers, and 80% of the
babies of vaccinated mothers (p <0.001). Zuccotti et al. [59]
found that immunizing pregnant women with the pandemic
MF59-adjuvanted vaccine during the last trimester of preg-
nancy induced protective antibody titres (HAI > 1:40) in
both maternal and newborn blood samples, and that pas-
sively acquired serum antibody levels persisted in most of
the infants for at least 5 months.
Further data regarding the possibility of protecting young
infants against influenza come from studies comparing the
incidence of the disease in children born of vaccinated moth-
ers with that in those born of non-vaccinated women [60–
64]. All of these studies (with the exception of the one by
France et al., [60] who did not evaluate the impact of vacci-
nation on influenza but on the total number of respiratory
illnesses) demonstrated that influenza vaccination of the
mother significantly reduces the risk of disease in the infant
for several months. A randomized trial carried out in Bangla-
desh has shown that the vaccination of pregnant women not
only induced antibody titres in the infant that were high
enough to suggest protection from birth until the age of
20 weeks, but also reduced the rates of influenza in the
infants in the first 6 months of life by about 63% [61]. Poeh-
ling et al. [62] have reported that hospitalized infants whose
mothers received influenza vaccine during pregnancy were
45–48% less likely to have laboratory-confirmed influenza
during their first influenza season than those of unvaccinated
mothers. Benowitz et al. [63] found that influenza vaccine
given to mothers during pregnancy was 91.5% effective in
preventing the hospitalization of their infants in their first
6 months of life. Finally, Eick et al. [64] have reported that
the infants of vaccinated mothers had a 41% reduction in the
risk of laboratory-confirmed influenza infection, and a 39%
reduction in the risk of hospitalization for influenza-like ill-
ness.
However, despite the importance of influenza vaccination
for mother and child, and although TIV has been largely
demonstrated to be safe and well tolerated by both [65,66],
vaccination coverage in pregnant women has remained very
poor. Estimated influenza vaccination coverage among preg-
nant women in the USA before 2009 was no higher than
15% [67]. Vaccination levels increased substantially in
response to the 2009 influenza pandemic: coverage reached
50% in the USA, and a recent survey of a limited number of
pregnant women seems to suggest that they remained at this
level in the 2010–2011 season, when 49% of pregnant
women reported that they had received the vaccine [67]. In
the European Union, where only eight countries recommend
influenza vaccination for pregnant women [68] and where
even the use of the pandemic influenza vaccine was very
poor [69–71], it is highly likely that influenza vaccination cov-
erage during pregnancy remains lower than in USA and has
not been influenced by the recent pandemic.
In the USA, it has been demonstrated that pregnant
women offered influenza vaccination by a healthcare provider
were more likely to be vaccinated than other women (71%
vs. 14%) [67] but, unfortunately, a number of reports have
underlined that healthcare providers do not systematically
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recommend influenza vaccination during pregnancy because
they are not convinced of the clinical importance of the dis-
ease or of the efficacy of the influenza vaccine [72–74]. Only
continued efforts to encourage healthcare providers to rec-
ommend and offer influenza vaccination to pregnant women
will permit a simultaneous reduction in the impact of influ-
enza on pregnancy and the problem of effective protection
against influenza in the first 6 months of life. Obviously, only
TIV should be used to reach this goal because live attenuated
influenza vaccine cannot be administered (as is the case for
all live vaccines).
Conclusions
A number of studies of different vaccines indicate that
maternal immunization can be useful in protecting infants in
the first months of life when the risk of vaccine-preventable
diseases is great, and the child is too young to be vaccinated
or too young to have completed the recommended sche-
dule. However, this strategy should be applied only in the
case of selected diseases in selected geographic areas, paying
particular care to the characteristics of both mother and
child, as this is the only way to obtain the best results. More
data collected and reported in a systematic way regarding
the effectiveness and the safety of vaccine products during
pregnancy are needed and could be captured from well-
designed, prospective, case–control studies. We also need
studies to assess the best approaches to increase immuniza-
tion coverage of pregnant women, to determine the ideal
venues for their immunization, and to test strategies that
promote postpartum immunization of mothers and families
of neonates. Finally, educational intervention targeting health-
care providers in charge of pregnant women should be
urgently implemented to further support the acceptance of
vaccination during pregnancy.
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